Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response

por Boziki, Marina, Bakirtzis, Christos, Sintila, Styliani-Aggeliki, Kesidou, Evangelia, Gounari, Evdoxia, Ioakimidou, Aliki, Tsavdaridou, Vasiliki, Skoura, Lemonia, Fylaktou, Asimina, Nikolaidou, Vasiliki, Stangou, Maria, Nikolaidis, Ioannis, Giantzi, Virginia, Karafoulidou, Eleni, Theotokis, Paschalis, Grigoriadis, Nikolaos
Publicado 2022